Research programme: antisense oligonucleotide centyrin conjugates - Aro Biotherapeutics/Ionis Pharmaceuticals
Latest Information Update: 28 Feb 2025
At a glance
- Originator Aro Biotherapeutics; Ionis Pharmaceuticals
- Class Antisense oligonucleotides; Centyrin drug conjugates; Centyrins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Muscular dystrophies; Unspecified
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for research development in Unspecified in USA (Parenteral)
- 28 Feb 2024 No recent reports of development identified for research development in Muscular-dystrophies in USA (Parenteral)
- 12 Jan 2021 Early research in Unspecified in USA (Parenteral), prior to January 2021